logo

Daré Bioscience, Inc (DARE)



Trade DARE now with
  Date
  Headline
8/12/2021 8:14:32 AM Daré Bioscience Q2 Loss Per Share $0.18 Vs Loss $0.21 Last Year
6/28/2021 8:29:57 AM Daré Bioscience Announces Positive Topline Results From Phase 1 Trial Of DARE-HRT1
3/24/2021 8:26:23 AM Daré Bioscience Begins Phase 2b RESPOND Study Of Sildenafil Cream, 3.6% In Women With Female Sexual Arousal Disorder
12/7/2020 8:16:00 AM Daré Bioscience Phase 3 Trial Of DARE-BV1 Trial Met Its Primary Endpoint
9/1/2020 8:13:01 AM Daré Bioscience And Avomeen Sign Strategic Partnership
8/20/2020 8:10:05 AM Daré Bioscience Announces Publication Of DARE-BV1 Proof Of Concept Study For Bacterial Vaginosis
7/27/2020 8:22:53 AM Daré Bioscience Begins Phase 1 Clinical Trial Of DARE-HRT1
6/17/2020 8:15:34 AM Daré Bioscience Begins Pivotal Phase 3 Study Of DARE-BV1 In Patients With Bacterial Vaginosis
1/13/2020 9:36:24 AM Bayer Signs License Agreement With Daré Bioscience
1/13/2020 7:11:09 AM Bayer To Commercialize Dar Bioscience's Investigational contraceptive Product Ovaprene In The U.S. Once Approved By FDA